FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Fang, DGD; Zhu, HR; Tang, QQ; Wang, GF; Min, P; Wang, QX; Li, N; Yang, DJ; Zhai, YF

Zhai, YF (通讯作者)，Ascentage Pharma Suzhou Co Ltd, 218 Xinghu St, Suzhou, Jiangsu, Peoples R China.

TRANSLATIONAL ONCOLOGY, 2022; 15 (1):

Abstract

Introduction: FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Desp......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索